Rociletinib (XegafriTM, CO-1686) (65), developed by Clovis Oncology, is a specific mutant agent for the treatment of NSCLC, belonging to the third-generation EGFR TKIs.190,191 In the EGFRT790M, the anilinopyrimidine group in rociletinib forms two hydrogen bonds with Met793 amide and carbonyl backbone, which became a hydrophobic interaction in the T790M structure. Here, EGFR is linked to non-small cell lung carcinoma.